Steroid

Santhera Receives Positive CHMP Opinion Recommending Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy

Retrieved on: 
금요일, 10월 13, 2023

Santhera plans for a first commercial launch in Germany in Q1-2024, subject to approval by the EC.

Key Points: 
  • Santhera plans for a first commercial launch in Germany in Q1-2024, subject to approval by the EC.
  • “We are thrilled about the CHMP’s positive opinion, which recognizes the urgent medical need for an effective and well tolerated treatment for this devastating disease.
  • “We are very excited about the positive opinion from the European Medicines Agency,” declared Ezio Magnano, President of Parent Project Italy.
  • A marketing authorization decision from the EC is expected within approximately two months of the positive CHMP opinion.

We landed a camera on Venus before seeing parts of our own oceans – it’s time to ramp up observations closer to home

Retrieved on: 
화요일, 10월 17, 2023

Its much denser atmosphere enables a greenhouse effect on steroids, with surface temperatures approaching 500°C.

Key Points: 
  • Its much denser atmosphere enables a greenhouse effect on steroids, with surface temperatures approaching 500°C.
  • We have managed to land a camera on the surface of Venus, with the Soviet space probe Venera 9 in 1975.
  • Like the “Earth rise” image captured during the Apollo 8 mission in 1968, this again proved the power of visual imagery.

Direct observations

    • But as powerful and all-encompassing as these observations are, we still make surprise discoveries, such as vent systems on the seafloor and life in under-ice cavities.
    • This is why we need to continue exploring and ramp up our capacity to measure the oceans directly.
    • Nowhere is this more true than in the Southern Ocean, the connector of all oceans.

Fostering collaboration

    • While it is not quite Venus in terms of difficulty, measurements have to target and prioritise the major science questions.
    • Earlier this year, more than 300 researchers gathered for the first Southern Ocean Observing Symposium in Hobart to express their growing concern.

The risks of the unknown

    • It isn’t cheap to track changes in such a remote location.
    • Sending ships and deploying robust instrumentation, and then retrieving the gear and data, all adds up.
    • The lack of direct observations is one reason we continue to be surprised by changes in the region.

FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With Resectable (T≥4 cm or N+) NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as a Single Agent as Adjuvant Treatment After Surgery

Retrieved on: 
화요일, 10월 17, 2023

With this approval, KEYTRUDA has six indications in NSCLC, across both metastatic and earlier stages of NSCLC.

Key Points: 
  • With this approval, KEYTRUDA has six indications in NSCLC, across both metastatic and earlier stages of NSCLC.
  • The EFS results, which were from the first interim analysis, were published in June 2023 in the New England Journal of Medicine.
  • Adverse reactions occurring in patients with resectable NSCLC receiving KEYTRUDA in combination with platinum-containing chemotherapy, given as neoadjuvant treatment and continued as single agent adjuvant treatment, were generally similar to those occurring in patients across tumor types receiving KEYTRUDA in combination with chemotherapy.
  • Eighty-one percent of patients in the KEYTRUDA in combination with platinum-containing chemotherapy arm had definitive surgery compared to 76% of patients in the placebo in combination with platinum-containing chemotherapy arm.

Albert Invent Transforms the Lab With its Worksheet: Replacing Excel, Removing Tedious Processes, and Bringing R&D Data Into a Single, Connected Source of Truth

Retrieved on: 
목요일, 10월 12, 2023

OAKLAND, Calif., Oct. 12, 2023 /PRNewswire-PRWeb/ -- Albert Invent, the company accelerating R&D with its data-driven, end-to-end platform, today announced the evolution of its Worksheet product. It now brings all of scientists' data, formulas, and materials into one connected command center that integrates with the full R&D ecosystem, giving them the ability to understand their experiments and data at scale in real time. As part of its ongoing commitment to expediting innovation and driving productivity while reducing costs for customers, Albert Invent's next generation Worksheet is a true replacement for Excel, with an extensible database sitting behind it. The result is a first-of-its-kind experience for chemical and materials scientists who develop the products we use every day. The new Worksheet enables even greater IP protection, fewer experiment iterations, and increased cost savings in addition to reducing errors and fostering greater collaboration.

Key Points: 
  • The result is a first-of-its-kind experience for chemical and materials scientists who develop the products we use every day.
  • "Albert Invent's next generation Worksheet is a true replacement for Excel, with an extensible database sitting behind it.
  • The result is a first-of-its-kind experience for chemical and materials scientists who develop the products we use every day".
  • At its core, Worksheet is a connected space where scientists can design formulations and access experiment data in real time.

Sosei Heptares and Verily Nominate First G-protein-coupled receptor Target for Therapeutic Development

Retrieved on: 
수요일, 10월 4, 2023

Sosei Group Corporation ("Sosei Heptares"; TSE: 4565) and Verily, an Alphabet precision health technology company, today announced the successful validation and nomination of a first G-protein-coupled receptor (GPCR) target into early drug discovery for immune-mediated diseases with an initial indication focus of inflammatory bowel disease (IBD).

Key Points: 
  • Sosei Group Corporation ("Sosei Heptares"; TSE: 4565) and Verily, an Alphabet precision health technology company, today announced the successful validation and nomination of a first G-protein-coupled receptor (GPCR) target into early drug discovery for immune-mediated diseases with an initial indication focus of inflammatory bowel disease (IBD).
  • This scientific breakthrough between the companies is the first research milestone stemming from the strategic collaboration announced in 2022 that brings together the complementary capabilities of Verily's immune profiling technology and Sosei Heptares' GPCR structure-based drug design (SBDD) platform.
  • Matt Barnes, President of Heptares Therapeutics and Head of UK R&D at Sosei Heptares, commented: “Our SBDD platform has proven to be highly productive in generating pre-clinical and clinical candidates against GPCR drug targets across multiple disease areas.
  • There is no cure for IBD, and current medications such as steroids and immunosuppressants used to slow the progression of disease have varying levels of efficacy.

Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Optometry Annual Meeting

Retrieved on: 
수요일, 10월 4, 2023

Bausch + Lomb acquired the Blink brand of eye drops for dry eyes and contacts from Johnson & Johnson Vision earlier this year.

Key Points: 
  • Bausch + Lomb acquired the Blink brand of eye drops for dry eyes and contacts from Johnson & Johnson Vision earlier this year.
  • Another educational event will highlight practical patient cases using products from across the company’s consumer, vision care and pharmaceutical portfolios.
  • The Bausch + Lomb schedule at AAOpt:
    “Clinical Dry Eye Findings in Patients Using a Novel Lipid-Containing Eye Drop.” Joshi et al.
  • “Perfluorohexyloctane, an Eye Drop for Dry Eye Disease, Reduces Corneal Staining Across All Regions of the Cornea.” Fahmy et al.

Ethos Discovery and Gallant Therapeutics Collaborate on Study Evaluating Gallant’s Stem Cell Therapy in Pugs with Necrotizing Meningoencephalitis (NME), also referred to as Pug Dog Encephalitis (PDE)

Retrieved on: 
화요일, 10월 3, 2023

Within 24 hours, Walter was diagnosed with pug dog encephalitis (PDE), a common name for necrotizing meningoencephalitis (NME) because it occurs most commonly in that breed.

Key Points: 
  • Within 24 hours, Walter was diagnosed with pug dog encephalitis (PDE), a common name for necrotizing meningoencephalitis (NME) because it occurs most commonly in that breed.
  • Despite aggressive therapy with steroids, immunosuppressants, and anti-seizure medications, Walter died within 24 hours of his diagnosis.
  • In this third study in the program, Ethos Discovery and Gallant Therapeutics are investigating treatment with Gallant’s MSCs in pugs previously screened for NME.
  • To learn more about enrolling your pug in the study, please visit: https://www.ethosdiscovery.org/clinical-study/necrotizing-meningoencepha....

AI disinformation is a threat to elections − learning to spot Russian, Chinese and Iranian meddling in other countries can help the US prepare for 2024

Retrieved on: 
금요일, 9월 29, 2023

Elections around the world are facing an evolving threat from foreign actors, one that involves artificial intelligence.

Key Points: 
  • Elections around the world are facing an evolving threat from foreign actors, one that involves artificial intelligence.
  • Countries trying to influence each other’s elections entered a new era in 2016, when the Russians launched a series of social media disinformation campaigns targeting the U.S. presidential election.
  • Over the next seven years, a number of countries – most prominently China and Iran – used social media to influence foreign elections, both in the U.S. and elsewhere in the world.
  • It’s not clear how these technologies will change disinformation, how effective they will be or what effects they will have.

A conjunction of elections

    • Seventy-one percent of people living in democracies will vote in a national election between now and the end of next year.
    • Nine African democracies, including South Africa, will have elections in 2024.
    • Australia and the U.K. don’t have fixed dates, but elections are likely to occur in 2024.
    • Many of those elections matter a lot to the countries that have run social media influence operations in the past.

Election interference

    • They talked about their expectations regarding election interference in 2024.
    • Of course, there’s a lot more to running a disinformation campaign than generating content.
    • A Columbia Journalism Review study found that most major news outlets used Russian tweets as sources for partisan opinion.
    • And the current crop of generative AIs are being connected to tools that will make content distribution easier as well.
    • These persona bots, as computer scientist Latanya Sweeney calls them, have negligible influence on their own.

Disinformation on AI steroids

    • Countries like Russia and China have a history of testing both cyberattacks and information operations on smaller countries before rolling them out at scale.
    • Countering new disinformation campaigns requires being able to recognize them, and recognizing them requires looking for and cataloging them now.
    • Disinformation campaigns in the AI era are likely to be much more sophisticated than they were in 2016.
    • There have been some important democratic elections in the generative AI era with no significant disinformation issues: primaries in Argentina, first-round elections in Ecuador and national elections in Thailand, Turkey, Spain and Greece.

NEW STUDY REVEALS THAT SOME CHILDREN WITH COMMON FORM OF ECZEMA SHOULD ALSO BE TESTED FOR ALLERGIC REACTIONS

Retrieved on: 
화요일, 9월 26, 2023

ROSEMONT, Ill., Sept. 26, 2023 /PRNewswire/ -- Eczema, which is a group of medical conditions that causes inflamed, irritated, and often itchy skin, affects millions of people worldwide. A new article published in the Journal of the American Academy of Dermatology reveals that children diagnosed with a type of eczema called atopic dermatitis – which they usually develop by 5 years of age – may also need to be tested for a second type of eczema called allergic contact dermatitis, which has similar symptoms and can be triggered by a range of substances that cause an allergic reaction.

Key Points: 
  • "It turns out that most of the things that I'm allergic to are very common ingredients in a lot of products," Schoeben said.
  • Poison ivy, poison oak and poison sumac are the most common causes of allergic reactions in the United States.
  • Other common causes of allergic contact dermatitis include metals (such as nickel), rubber, dyes, cosmetics, preservatives, and fragrances.
  • In these cases, the overall eczema may look very severe but once you remove the allergic component, the eczema seems much more manageable.

Volpi Foods Introduces New Product: Salami Stix

Retrieved on: 
화요일, 9월 26, 2023

Salami Stix are made with minimal, all-natural ingredients, making them a great snacking solution for people always on the go.

Key Points: 
  • Salami Stix are made with minimal, all-natural ingredients, making them a great snacking solution for people always on the go.
  • "We are excited to introduce our newest product, Stix, to our customers," said Lorenza Pasetti, CEO of Volpi Foods.
  • Volpi Foods exclusively sources from local Midwest farmers to ensure that every animal comes with their signature Raised Responsibly™ standards.
  • Volpi Salami Stix will be available in grocery stores across the United States in September.